Aug 8, 2017

Achaogen to Present at the Wedbush PacGrow Healthcare Conference

Company presentation scheduled for August 15, 2017 at 10:55 a.m. EDT

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the Company will be presenting at the 2017 Wedbush PacGrow Healthcare Conference taking place August 15 to 16, 2017 at the Le Parker Meridien hotel in New York, NY. Achaogen's management will present at 10:55 a.m. Eastern Daylight Time on Tuesday, August 15th, 2017.

A link to the live audio webcast of the presentation, and a replay of the presentation for 30 days following the conference, will be available in the "Investors" section of Achaogen's website,

About Achaogen
Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments for MDR gram-negative infections. Achaogen is developing plazomicin, Achaogen's lead product candidate, for the treatment of serious bacterial infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. The Food and Drug Administration has granted plazomicin Breakthrough Therapy designation for the treatment of bloodstream infections caused by certain Enterobacteriaceae in patients who have limited or no alternative treatment options. Achaogen's plazomicin program is funded in part with a contract from the Biomedical Advanced Research and Development Authority. The Company's second product candidate is C-Scape, an orally-administered beta-lactam/beta-lactamase inhibitor combination. Achaogen has other programs in early and late preclinical stages focused on other MDR gram-negative infections and additional disease areas. All product candidates are investigational only and have not been approved for commercialization. For more information, please visit

Achaogen Contact: 
David Arrington
Vice President, Investor Relations and Corporate Communications